Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA054347-02S1
Application #
3198873
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1991-09-18
Project End
1995-02-28
Budget Start
1992-03-01
Budget End
1993-02-28
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
Schools of Arts and Sciences
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Madalengoitia, J S; Tepe, J J; Werbovetz, K A et al. (1997) Structure-activity relationship for DNA topoisomerase II-induced DNA cleavage by azatoxin analogues. Bioorg Med Chem 5:1807-15
Cline, S D; Macdonald, T L; Osheroff, N (1997) Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Biochemistry 36:13095-101
Tepe, J J; Madalengoitia, J S; Slunt, K M et al. (1996) Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain. J Med Chem 39:2188-96
Slunt, K M; Grace, J M; Macdonald, T L et al. (1996) Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother 40:706-9
Werbovetz, K A; Spoors, P G; Pearson, R D et al. (1994) Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol Biochem Parasitol 65:1-10
Werbovetz, K A; Lehnert, E K; Macdonald, T L et al. (1992) Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob Agents Chemother 36:495-7
Leteurtre, F; Madalengoitia, J; Orr, A et al. (1992) Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin. Cancer Res 52:4478-83